Author Archives: Warren Woessner

Inequitable Conduct Lives! Therasense Update and Refresher

On November 3 at 12:30 EST, I will be participating in an AIPLA webinar with Prof. David Hricik (Mercer College of Law) and William Covey, Director of the OED at the USPTO. We will present: Inequitable Conduct Lives! This presentation … Continue reading

Posted in Inequitable Conduct/Rule 56 | Tagged , | Leave a comment

CareDx v. Natera – Are Processing Steps Known to the Art Always “Conventional”?

In CareDx (Stanford U.) v. Natera Civ. Action No. 19-0567-CFC-CJB Consolidated (Sept. 28, 2021, D. Delaware), Judge Connolly ruled that the diagnostic method claimed in U. S. Pat. No. 8,703,652 and two others was a patent-ineligible natural phenomenon. The method … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

Belcher v. Hospira – Inequitable Conduct is Still in Your Invalidity Toolbox

Ever since Therasense made it more difficult to plea and prove inequitable conduct (IC), I feel that practitioners and litigators have pushed this defense to patent infringement out of the front lines of infringement attacks. In fact, I know of … Continue reading

Posted in Inequitable Conduct/Rule 56 | Tagged | Leave a comment

Chemours Co. v. Daikin Industries – Back to Some IP Basics

After trying to untie the Gordian knot of patent eligibility, it is almost IP comfort food to read a Fed. Cir. decision that deals with obviousness. In Chemours Co. FC, LLC v Daikin Industries, Ltd., Appeal Nos. 2020-1289 and 2020-1290 … Continue reading

Posted in Obviousness | Tagged , | Leave a comment